The effectiveness of leronlimab in ARDS is going to depend on how far ARDS has progressed. In very early stages where shortness of breath is occuring due to fluid filled air sacs caused by inflammation leronlimab will reverse it with little to no apparent damage to pulmonary cells. At a later stage there may be some lung damage that will result in reduced lung capacity. If it's very late stage before any type of treatment is started and there is heavy critical damage to organs due to oxygen deprivation it may be to late to save the patient.

Quote:

---

In turn, antibodies to the platelet-derived chemokines CCL5 and CXCL4, pharmacological disruption of the CCL5-CXCL4 heteromers or, neutralization of CCR5 diminish lung edema, neutrophil infiltration, and tissue damage in LPS-,acid- and sepsis-induced ALI /quote]
https://journals.plos.org/plosone/article?id=...ne.0161218

---